[go: up one dir, main page]

AR069409A1 - Variantes de peptidos natriureticos de tipo c - Google Patents

Variantes de peptidos natriureticos de tipo c

Info

Publication number
AR069409A1
AR069409A1 ARP080105079A ARP080105079A AR069409A1 AR 069409 A1 AR069409 A1 AR 069409A1 AR P080105079 A ARP080105079 A AR P080105079A AR P080105079 A ARP080105079 A AR P080105079A AR 069409 A1 AR069409 A1 AR 069409A1
Authority
AR
Argentina
Prior art keywords
variants
cnp
type
amino acids
natural peptides
Prior art date
Application number
ARP080105079A
Other languages
English (en)
Inventor
Emil D Kakkis
Dong Wei
Dan J Wendt
Joshua R Bliesath
Sean Bell
Mika Aoyagi-Scharber
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40364250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR069409(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of AR069409A1 publication Critical patent/AR069409A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Variantes del péptido natriurético de tipo C (CNP) que comprende una o más supresiones; adiciones y/o sustituciones con aminoácidos naturales, aminoácidos no naturales y/o peptidomiméticos (incluyendo isosteros de enlaces péptidos); extensiones de aminoácidos; y/u otros grupos químicos tales como, por ejemplo, poli(etilenglicol) y ácidos hidrofobicos. Las variantes de CNP son de utilidad como agentes terapéuticos para el tratamiento de enfermedades que responden a CNP, incluyendo en un sentido no limitativo trastornos relacionados con los huesos tales como, por ejemplo, displasias del esqueleto y acondroplasia, y trastornos de la musculatura lisa vascular tales como, por ejemplo, restenosis y arteriosclerosis.
ARP080105079A 2007-11-21 2008-11-21 Variantes de peptidos natriureticos de tipo c AR069409A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98949707P 2007-11-21 2007-11-21
US6148808P 2008-06-13 2008-06-13

Publications (1)

Publication Number Publication Date
AR069409A1 true AR069409A1 (es) 2010-01-20

Family

ID=40364250

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080105079A AR069409A1 (es) 2007-11-21 2008-11-21 Variantes de peptidos natriureticos de tipo c

Country Status (10)

Country Link
US (1) US8377884B2 (es)
EP (1) EP2217620A2 (es)
JP (1) JP2011504506A (es)
AR (1) AR069409A1 (es)
AU (1) AU2008326327A1 (es)
CA (1) CA2705603A1 (es)
CL (1) CL2008003476A1 (es)
PE (1) PE20091067A1 (es)
TW (1) TWI367213B (es)
WO (1) WO2009067639A2 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1759001T3 (da) 2004-04-21 2011-08-01 Enobia Pharma Inc Konjugat til tilførsel til knogler og fremgangsmåde til fremstilling deraf ved at målrette proteiner til knoglen
BR122019026832B1 (pt) * 2009-05-20 2021-08-24 Biomarin Pharmaceutical Inc Variantes de peptídeo natriurético tipo c (cnp), seu método de produção recombinante e seu uso, composição farmacêutica, composição para tratamento de uma condição ou distúrbio responsivo a cnp e célula hospedeira para produção in vitro de um peptídeo cnp
JP2011026294A (ja) * 2009-06-26 2011-02-10 Canon Inc 化合物
JP4834190B2 (ja) 2009-07-23 2011-12-14 株式会社 イギス 皮膚外用剤組成物
ES2556336T3 (es) 2009-08-27 2016-01-15 Kyoko Endo Agente terapéutico para la rinitis
KR20180049198A (ko) * 2009-09-25 2018-05-10 샤이어 오펀 테라피즈 게엠베하 신규한 ｎｐｒ－ｂ 길항제
WO2011075471A2 (en) * 2009-12-18 2011-06-23 Alcon Research, Ltd. Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders
AR078446A1 (es) 2009-12-18 2011-11-09 Alcon Res Ltd Agonistas de npr-b. uso.
US20110300071A1 (en) * 2010-06-04 2011-12-08 Washington University Targeting npr-c in angiogenesis and atherosclerosis with a c-type atrial natriuretic factor (canf)-comb nanocomplex
AU2011350066A1 (en) 2010-12-27 2013-07-11 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
EP2666475B1 (en) 2011-01-21 2017-08-16 Igisu Co., Ltd. Therapeutic agent for alopecia
CN103402542B (zh) 2011-02-28 2017-05-03 独立行政法人国立循环器病研究中心 恶性肿瘤转移抑制用药物
WO2013027680A1 (ja) 2011-08-19 2013-02-28 独立行政法人国立循環器病研究センター ナトリウム利尿ペプチド受容体gc-aアゴニスト及びgc-bアゴニストを組み合わせてなる悪性腫瘍の増悪防止用医薬
SG11201401605QA (en) 2011-10-19 2014-09-26 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2013095759A1 (en) * 2011-12-23 2013-06-27 Mayo Foundation For Medical Education And Research Assessing renal structural alterations and outcomes
EP2853273A4 (en) * 2012-04-25 2016-01-13 Daiichi Sankyo Co Ltd PROMOTER FOR BONE REPAIR
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US20150216860A1 (en) 2013-03-10 2015-08-06 National University Corporation Nagoya University Therapeutic agent for systemic bone disease and use thereof
JPWO2015129812A1 (ja) * 2014-02-27 2017-03-30 第一三共株式会社 ステロイド剤投与で誘発される成長障害に対する医薬
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
CA2967851C (en) 2014-12-05 2024-02-27 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
RU2728656C2 (ru) * 2015-01-09 2020-07-31 Асцендис Фарма Гроус Дизордерс А/С Cnp пролекарства
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
HUE066258T2 (hu) 2015-07-30 2024-07-28 Biomarin Pharm Inc A C-típusú natriuretikus peptid variánsok alkalmazása a csontrendszeri diszplázia kezelésére
EP3330280A4 (en) * 2015-07-31 2019-06-12 Igisu Co., Ltd. CYCLIC PEPTIDE CNP AND MEDICINE, PREPARATION FOR EXTERNAL USE AND COSMETIC PRODUCT, CONTAINING ALL OF SAID CYCLIC PEPTIDE
AU2016308624B2 (en) 2015-08-17 2022-06-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
US11229686B2 (en) 2015-09-28 2022-01-25 Alexion Pharmaceuticals, Inc. Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
HUE057083T2 (hu) 2015-12-08 2022-04-28 Biomarin Pharm Inc C-típusú nátriuretikus peptid változatainak alkalmazása oszteoartritisz kezelésére
WO2017118707A1 (en) * 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
NZ743488A (en) * 2016-01-08 2023-02-24 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with low initial npr-b activity
WO2017118693A1 (en) * 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
CN115177720A (zh) * 2016-01-08 2022-10-14 阿森迪斯药物生长障碍股份有限公司 具有低npr-c结合的控制释放cnp激动剂
CA3008015A1 (en) * 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release c-type natriuretic peptide agonists with increased neutral endopeptidase stability
AU2017205688C1 (en) 2016-01-08 2022-03-10 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
US11186832B2 (en) 2016-04-01 2021-11-30 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
CA3021644A1 (en) * 2016-05-06 2017-11-09 Phasebio Pharmaceuticals, Inc. Elp fusion proteins for controlled and sustained release
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
WO2018035420A1 (en) 2016-08-18 2018-02-22 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
EP4223309A1 (en) 2016-09-29 2023-08-09 Ascendis Pharma Growth Disorders A/S Combination therapy with controlled-release cnp agonists
EP3574913A4 (en) 2017-01-24 2020-07-22 Daiichi Sankyo Company, Limited SMALL SIZE THERAPEUTIC AGENT
MY201165A (en) * 2017-03-22 2024-02-08 Pharmain Corp Npra agonists, compositions, and uses thereof
KR20240158374A (ko) 2017-03-31 2024-11-04 알렉시온 파마슈티칼스, 인코포레이티드 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
JP2021519590A (ja) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質の製造
EP3553079A1 (en) * 2018-04-12 2019-10-16 Bayer Aktiengesellschaft C-type natriuretic peptide engrafted antibodies
WO2020033867A2 (en) 2018-08-10 2020-02-13 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
CN113423384B (zh) 2019-02-11 2024-01-05 阿森迪斯药物生长障碍股份有限公司 Cnp缀合物的干燥药物制剂
CA3161266A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
CN115803338A (zh) * 2020-06-12 2023-03-14 药明公司 C型利尿钠肽及其治疗急性肺损伤的方法
EP4164672A4 (en) * 2020-06-12 2024-10-09 PharmaIN Corporation C-TYPE NATRIURETIC PEPTIDES AND RELATED METHODS IN THE TREATMENT OF CANCER
CN111848776B (zh) * 2020-08-31 2022-03-18 江苏璟泽生物医药有限公司 聚乙二醇修饰的rhBNP及其制备方法
US12083169B2 (en) 2021-02-12 2024-09-10 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
MX2024000526A (es) 2021-07-09 2024-02-02 Biomarin Pharm Inc Variantes del peptido natriuretico tipo c para tratar la displasia esqueletica en ni?os.
JP2024546728A (ja) * 2021-12-07 2024-12-26 バイオマリン ファーマシューティカル インコーポレイテッド Ｃｎｐ療法
AU2022413318A1 (en) 2021-12-13 2024-05-16 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
CN116554267A (zh) * 2022-01-30 2023-08-08 江苏众红生物工程创药研究院有限公司 聚乙二醇修饰的激肽或其变体和药物应用
IL316466A (en) 2022-05-23 2024-12-01 Ascendis Pharma Growth Disorders As Liquid pharmaceutical formulations of cnp compounds
US12077561B2 (en) * 2022-11-02 2024-09-03 Novo Nordisk A/S CNP compounds
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
KR20250162619A (ko) 2023-03-20 2025-11-18 아센디스 파마 그로우쓰 디스오더스 에이/에스 연골무형성증을 가진 인간 대상에서의 흉요추 변형의 치료 방법

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0478797T3 (da) * 1990-04-20 1995-06-26 Hisayuki Matsuo Nyt fysiologisk aktivt peptid stammende fra gris
JP2930380B2 (ja) 1990-07-13 1999-08-03 壽之 松尾 ブタ由来新規生理活性ペプチド（ｃｎｐ―５３）
JP3026351B2 (ja) 1990-07-13 2000-03-27 壽之 松尾 ブタｃｎｐ遺伝子及び前駆体蛋白
JP3026354B2 (ja) * 1990-09-27 2000-03-27 壽之 松尾 ヒトｃｎｐ遺伝子及び前駆体蛋白
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JP2809533B2 (ja) * 1991-01-31 1998-10-08 壽之 松尾 Ｃｎｐ類似体ペプチド
AU6360394A (en) 1993-03-03 1994-09-26 Mayo Foundation For Medical Education And Research Vasonatrin peptide and analogs thereof
US5665704A (en) * 1993-11-12 1997-09-09 Genentech, Inc. Receptor specific atrial natriuretic peptides
US5846932A (en) 1993-11-12 1998-12-08 Genentech, Inc. Receptor specific atrial natriuretic peptides
US5917019A (en) * 1997-02-13 1999-06-29 The Rockefeller University Altered telomere repeat binding factor 2
US6136040A (en) 1998-03-05 2000-10-24 Washington University Animal model with disrupted FGF-9 gene
IL125958A0 (en) * 1998-08-27 1999-04-11 Yeda Res & Dev Animal model for fibroblast growth factor receptor associated chondrodysplasia
WO2000061631A1 (en) 1999-04-12 2000-10-19 Astrazeneca Ab Modified pentapeptide antagonists of the atrial natriuretic peptide clearance receptor
US6887470B1 (en) * 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6407211B1 (en) * 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
BRPI0203172B8 (pt) * 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
WO2004047871A2 (en) 2002-11-26 2004-06-10 Nobex Corporation Modified naturetic compounds, conjugates, and uses thereof
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
KR20070007842A (ko) * 2004-03-31 2007-01-16 카즈와 나카오 신장증가용 조성물
WO2010078325A2 (en) * 2008-12-29 2010-07-08 Mayo Foundation For Medical Education And Research Natriuretic polypeptides for reducing or preventing restenosis
AU2011350066A1 (en) * 2010-12-27 2013-07-11 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof

Also Published As

Publication number Publication date
US20100331256A1 (en) 2010-12-30
CA2705603A1 (en) 2009-05-28
CL2008003476A1 (es) 2009-08-14
TW200927758A (en) 2009-07-01
TWI367213B (en) 2012-07-01
WO2009067639A3 (en) 2009-07-09
WO2009067639A4 (en) 2009-09-11
PE20091067A1 (es) 2009-08-12
AU2008326327A1 (en) 2009-05-28
WO2009067639A2 (en) 2009-05-28
US8377884B2 (en) 2013-02-19
JP2011504506A (ja) 2011-02-10
EP2217620A2 (en) 2010-08-18

Similar Documents

Publication Publication Date Title
AR069409A1 (es) Variantes de peptidos natriureticos de tipo c
AR078044A1 (es) Variantes de peptidos natriureticos de tipo c
CO2019009587A2 (es) Polipéptidos de relaxina modificada que comprenden un mejorador farmacocinético y sus usos
MX2015008226A (es) Metodos para modular la homeostasis de los acidos biliares, y tratamiento de trastornos y enfermedades causadas por los acidos biliares.
ECSP14016014A (es) Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardíaca
MX340541B (es) Secuencias de aminoacidos mejoradas dirigidas contra virus sincitial respiratorio humano y polipeptidos que comprenden las mismas para la prevencion y/o tratamiento de infecciones del tracto respiratorio.
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
PE20090108A1 (es) Coagonistas del receptor de glucagon/glp-1
PE20180128A1 (es) Compuestos antisenescentes y usos de los mismos
IN2012DN00248A (es)
CO6231039A2 (es) Composiciones que comprenden anticuerpo que se fija al dominio ii de her2 y sus variantes acidas
GT200800273A (es) Polipeptidos de factor de crecimiento de tipo insulina estabilizada
AR093626A1 (es) Proteinas de fusion de enzima lisosomal y usos de las mismas
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
EA200901459A1 (ru) Реконструированные поверхностно-активные вещества, имеющие улучшенные свойства
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
AR078445A1 (es) Agonistas del peptido natriuretico tipo b (npr -b)
PE20121643A1 (es) Polipeptidos del factor ix modificados y usos de los mismos
CL2019003441A1 (es) Puestos de mic-1 y usos de estos.
PE20200894A1 (es) Polipeptidos variantes del factor de crecimiento tipo insulina 1
ECSP10010729A (es) Péptidos dirigidos a crkl
UY38200A (es) Conjugados de tirosina-tirosina de péptido cíclico acoplado a péptido de fusión de glp-1 y sus usos
MX2015002994A (es) Peptidos de inhibidores obtenidos del receptor desencadenante expresado en celulas mieloides de tipo 1 (trem-1) y transcrito similar a trem 1 (tlt-1) y usos de los mismos.
CO2022003556A2 (es) Análogos de compstatina y sus usos médicos

Legal Events

Date Code Title Description
FB Suspension of granting procedure